Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 3/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20156639 | 0.85 | AKR1B1 (0.32) | ALDH1A1CYP3A4 | |
| SCHEMBL18229665 | 0.84 | NAAA (0.31) | — | |
| SCHEMBL19829242 | 0.84 | NAAA (0.31) | — | |
| SCHEMBL18229672 | 0.78 | PKM (0.30) | ALDH1A1 | |
| SCHEMBL20156626 | 0.77 | TSHR (0.31) | ALDH1A1TSHR | |
| SCHEMBL18229668 | 0.76 | NAAA (0.32) | ALDH1A1TSHR | |
| SCHEMBL20150654 | 0.70 | NAAA (0.32) | ALDH1A1 | |
| SCHEMBL18229720 | 0.70 | KDM4E (0.31) | ALDH1A1 | |
| SCHEMBL18229721 | 0.70 | KDM4E (0.31) | ALDH1A1 | |
| SCHEMBL19832120 | 0.69 | AKR1B1 (0.32) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597401-B2 | Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180134724-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | CURIA BUFFALO R&D, LLC | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597401-B2 | Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof | MAOB, MAOA, NISCH | HPSE 1775/4885PTPN1 4083/4885CDC25B 141/4885 |
| US-20180134724-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | MAOB, MAOA, NISCH | HPSE 1775/4885PTPN1 4083/4885CDC25B 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.